WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and ...

WuXi Biologics (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and ...

WuXi Biologics and Sinorda Biomedicine have jointly announced a strategic collaboration for the development and manufacturing ...

On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, ...

HanchorBio and WuXi Biologics collaborate to develop fusion proteins using the Fc-Based Designer Biologics platform, targeting oncology and autoimmune diseases. WuXi Biologics offers end-to-end ...

China-based biologics services group WuXi Biologics (HKG: 2269) has entered a strategic collaboration with Sinorda ...

WuXi Biologics says the company will provide the partnership with integrated, end-to-end biologics development and manufacturing services.

WuXi Biologics and Sinorda Biomedicine collaborate to accelerate development and manufacturing of innovative bispecific antibody: Shanghai Friday, January 30, 2026, 10:00 Hrs [IST ...

AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.

SHANGHAI, Jan ...

If you are wondering whether WuXi Biologics (Cayman) is still attractively priced after its rebound, you are not alone. This article breaks down what the current share price might be implying about ...

Taiwanese biotech HanchorBio (TPEx: 7827) has signed a strategic collaboration with WuXi Biologics (HKEX: 2269) to develop ...